CHICAGO, IL—An exploratory genetic sequencing method has identified new and previously known variants downstream of clopidogrel metabolism that appear to influence on-treatment reactivity after percutaneous coronary intervention (PCI), according to results of the EXOME study presented March 24, 2012, at the annual American College of Cardiology/i2 Scientific Session. Over longer-term follow-up, the CYP2C18/19 locus is the primary protein-coding determinant of clopidogrel response variability.
Researchers led by Matthew J. Price, MD, of the Scripps Translational Research Institute (La Jolla, CA), acquired 1,152 samples obtained at platelet function screening or during follow-up from patients participating in the GRAVITAS trial at 42 sites. On-treatment ....
You must be logged in to access this content.
To continue, please enter your username and password above.
If you do not yet have a free TCTMD account, please:
For questions regarding the registration process, please refer to our FAQ documentation or contact customer service.